These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 19956951)

  • 1. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of long-term (5-year) survival in patients with metastatic breast cancer to the liver].
    Kan N
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1780-4. PubMed ID: 17212106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
    Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
    Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
    Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG; Malmgren JA; Atwood M
    Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of metastatic spread in triple-negative breast cancer.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.